A new study published in eClinicalMedicine has confirmed that a novel natural supplement—invented, researched, developed and commercialized at the Center for Addiction and Mental Health (CAMH)—prevents postpartum blues, ...
Apr 10, 2024
0
10
As part of a comprehensive effort to improve cancer screenings among diverse communities, Penn Medicine's Abramson Cancer Center (ACC) Community Outreach and Engagement team developed a culturally sensitive educational video ...
Apr 9, 2024
0
0
A new study from the University of Pennsylvania School of Nursing's Center for Health Outcomes and Policy Research (CHOPR)—published in JAMA Network Open—showed that, aside from retirements, poor working conditions are ...
Apr 9, 2024
1
5
Chimeric antigen receptor-T cell therapy (CAR-T cell therapy) could provide a revolutionary approach to organ transplantation for patients who are hard to match and susceptible to rejection, Mayo Clinic researchers discovered.
Apr 9, 2024
0
0
For patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, cadonilimab plus chemotherapy is associated with improved overall survival and progression-free survival, according to a study presented at the annual ...
Apr 8, 2024
0
0
A blood test appears capable of detecting early-stage pancreatic cancers with up to 97% accuracy, a new study reports.
Apr 8, 2024
0
1
The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal ...
Apr 8, 2024
0
0
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant ...
Apr 8, 2024
0
0
Americans seem to have quite a positive view of dietary supplements. According to a 2023 survey, 74% of U.S. adults take vitamins, prebiotics and the like.
Apr 8, 2024
0
0
A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using molnupiravir to treat COVID-19.
Apr 8, 2024
0
45
